Mankind Pharma Q3 Results: Profit Falls 16%, Misses Estimates
The company posted a net profit of Rs 380.2 crore in the third quarter as compared to Rs 453.8 crore in the year-ago period.
Mankind Pharma Ltd.'s consolidated net profit decreased 16% in the quarter ended December, missing analysts' estimates.
The company posted a net profit of Rs 380.2 crore in the third quarter as compared to Rs 453.8 crore in the year-ago period, according to an exchange filing on Thursday. Analysts tracked by Bloomberg had estimated a net profit of Rs 470 crore.
Revenue growth was driven by continued outperformance in Chronic, strong recovery in OTC and consolidation of Bharat serums and vaccines.
Decrease in net profit was led by increase in finance cost of the company. The finance cost increased 24 times due to acquisition of BSV.
Mankind Pharma Q3 FY25 Highlights (Consolidated, YoY)
Revenue up 24% to Rs 3,230 crore versus Rs 2,607 crore (Bloomberg estimate: Rs 3,180 crore).
Ebitda up 37% to Rs 829.8 crore versus Rs 606.5 crore (Bloomberg estimate: Rs 837 crore).
Margin at 25.7% versus 23.3% (Bloomberg estimate: 26.3%).
Profit down 16% to Rs 380.2 crore versus Rs 453.8 crore (Bloomberg estimate: Rs 470 crore).
Market share for the company grew from 4.4% in March 2024 to 4.8% in December 2024, driven by the BSV acquisition and strong leadership in the gynecology segment.
The company's consumer healthcare business saw strong revenue growth of 30% YoY, supported by steady growth across all key brands
Export saw a revenue growth of 121% YoY, driven by increase in the base business supported by new launches in last 12-24 months and consolidation of BSV
Shares of Mankind Pharma closed 4.1% higher at Rs 2,620 apiece on the NSE, compared to a 0.22% climb in the benchmark Nifty 50.
